AN ACT to provide for a legislative management study relating to the potential uses of kratom and the implementation of regulations of kratom in the state.
House Bill 1566 does not directly regulate kratom in North Dakota. Instead, it directs the Legislative Management to study the potential uses of kratom and possible regulatory approaches during the 2025-26 interim. The study is to examine kratom production, manufacturing, distribution, and retail sales, and then report findings, recommendations, and any draft legislation needed to the 70th Legislative Assembly.
Because the bill is a study resolution rather than a substantive regulatory measure, its immediate effect on state law is limited. It does not create licensing rules, criminal penalties, product standards, or consumer protections on its own. Its main legal impact is to authorize interim legislative review of kratom policy and to lay the groundwork for possible future legislation if the study identifies a need for regulation.
HB 1566 leaves existing state law unchanged in the short term, but it creates an official legislative process to evaluate whether kratom should be regulated and, if so, how. The study is broad enough to consider the full supply chain—production, manufacturing, distribution, and retail sale—which could lead to future statutes affecting businesses, sellers, and consumers involved with kratom products. Any actual legal changes would have to come later through separate legislation based on the study’s recommendations.
The bill appears to have received generally favorable support in both chambers, passing the House 83-9 and the Senate 31-15. That vote pattern suggests broad interest in examining kratom policy, even if there was not unanimity on the need for a study. The absence of recorded committee transcripts limits insight into detailed debate, but the final votes indicate the measure was acceptable to a majority of legislators.
The main point of contention is likely whether kratom warrants legislative attention and whether the state should move toward regulation, given that the bill itself does not impose any rules. Supporters likely viewed the study as a prudent way to gather information on a substance with potential uses and possible public health or market concerns. Opponents may have questioned the need for a state study, the wisdom of signaling future regulation, or whether kratom should be treated differently from other consumer products. Because there are no committee transcripts, the specific arguments and sponsors of those concerns are not documented in the provided materials.